Vanderbilt University Medical Center: Vulnerability Found in Immunotherapy-Resistant Triple-Negative Breast Cancer
October 05, 2023
October 05, 2023
NASHVILLE, Tennessee, Oct. 5 (TNSres) -- Vanderbilt University Medical Center issued the following news:
Researchers at Vanderbilt-Ingram Cancer Center have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Currently, only about 15% of early-stage, triple-negative breast cancer patients benefit from combining immunotherapy, drugs that target . . .
Researchers at Vanderbilt-Ingram Cancer Center have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Currently, only about 15% of early-stage, triple-negative breast cancer patients benefit from combining immunotherapy, drugs that target . . .